

REMARKS

Claims 1-6, 11 and 13-18 are pending in the instant application. Claims 1-6, 11 and 13-16 are allowed. Applicants have currently amended Claims 17-18. WHEREIN, Claims 17-18 remain to be examined. No new matter has been added. No additional claims fee is believed to be due. Applicants reserve the right to prosecute the originally filed claims in the future.

35 USC 112, first paragraph

The Examiner has rejected Claims 17-18 because the specification, while being enabling for using compounds of formula A wherein Q is pyrimidinylpyrazole in treating carcinoma, does not reasonably provide enablement for treating the scope of cancers of the claims encompassing any and all cancer.

Applicants have currently amended Claims 17-18 to delete "cancer" and replace with "carcinoma".

Applicants believe no additional fees are due but the Commissioner is authorized to charge any fees required in connection with this amendment to Merck Deposit Account No. 13-2755. If a telephonic communication with Applicant's representative will aid in the advancement of the prosecution of this application, please telephone the representative indicated below.

Respectfully submitted,

By: Matthew A. Leff, Reg. # 50149/
Matthew A. Leff
Registration No. 50,149
Attorney for Applicants

MERCK & CO., INC.
P.O. Box 2000 - RY 60-30
Rahway, New Jersey 07065-0907
Telephone No. (732) 594-1404

Date: April 15, 2009